Formycon AG (FSB: FYB, Prime Standard) announced today that it will publish its financial results for the fiscal year 2025 on April 22, 2026. The Management Board will discuss the company's development, key financial figures, and provide an outlook for the 2026 fiscal year during a conference call that will be broadcast live on the internet. The call is scheduled for Wednesday, April 22, 2026, at 3:00 PM (CEST) in English. Participants can register at https://webcast.meetyoo.de/reg/lNibT8TVWubG. After registration, a confirmation email with individual dial-in data will be sent. The presentation and audio broadcast can be accessed via https://www.webcast-eqs.com/formycon-2025-fy. Following a brief presentation, the Management Board will be available for analysts’ questions. The conference call will be recorded and subsequently accessible on the Formycon website at https://www.formycon.com/en/investor-relations/publications/.
In addition, representatives of the Management Board will attend several events and investor conferences in the second quarter of 2026. On May 11–12, 2026, CFO Enno Spillner will participate in the Equity Forum Spring Conference in Frankfurt, Germany. On May 28, 2026, the company will publish its results for the first quarter of 2026, followed by a conference call and webcast with CEO Dr. Stefan Glombitza, CFO Enno Spillner, CBO Nicola Mikulcik, and CSO Dr. Andreas Seidl. From June 2–4, 2026, CFO Spillner will attend the Jefferies Global Healthcare Conference in New York City, U.S. On June 8, 2026, the Management Board will participate in the mwb research Roundtable via webcast. The Annual General Meeting will take place on June 10, 2026, at Haus der Bayerischen Wirtschaft in Munich, Germany. Finally, on June 18, 2026, CFO Spillner will attend the UBS Life Sciences Conference in London, UK. A full financial calendar is available at https://www.formycon.com/en/investors/financial-calendar/.
Formycon AG is a leading independent developer of high-quality biosimilars, focusing on therapies in ophthalmology, immunology, immuno-oncology, and other key disease areas. The company covers almost the entire value chain from technical development through clinical trials to regulatory approval. For commercialization, Formycon relies on strong, well-trusted long-term partnerships worldwide. With FYB201/ranibizumab and FYB202/ustekinumab, Formycon already has two biosimilars on the market. Another biosimilar, FYB203/aflibercept, has been approved by the FDA, EMA, and MHRA. Four pipeline candidates – including FYB208/dupilumab – are currently in development. Through its biosimilars, Formycon aims to provide as many patients as possible with access to highly effective and affordable medicines.
The announcement of the fiscal year 2025 results and the upcoming investor conferences underscore Formycon's commitment to transparency and engagement with the investment community. As the biosimilar market continues to grow, with global sales currently around $21 billion and projected to exceed $74 billion by 2030, Formycon's progress in developing and commercializing biosimilars positions it to capture a significant share of this expanding market. The company's pipeline, including the promising FYB208/dupilumab, highlights its potential to address major therapeutic areas and generate long-term value for shareholders.
